WHO Contribution to impementing MeTA


Published on

The role of the World Health Organization (WHO) in the Medicines Transparency Alliance (MeTA), May 2008

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • Title of presentation 04/06/09 MeTA
  • WHO Contribution to impementing MeTA

    1. 1. Contribution to MeTA implementation in countries Gilles Forte WHO 06/04/09
    2. 2. Improving access to medicines as part of health systems strengthening Principles for collaboration with Countries Multi stakeholders approach Coordinated efforts within WHO Principles Enhanced capacity in regions and countries Based on country needs strategy & plans Information systems and Evidence Fulfil primary health care values Quality health service delivery Well performing health workforce Sustainable health financing Leadership and Governance Support countries for strengthening systems and capacity to achieve sustainable availability of affordable, quality, safe, efficacious medicines and their appropriate use OBJECTIVE
    3. 3. Coordinated efforts within WHO for efficient and sustainable collaboration with Countries HSS TCM PSM Other WHO Clusters AFRO AMRO EMRO EURO SEARO WPRO Country Offices NPO NPO NPO NPO
    4. 4. WHO hierarchical approach to monitor and assess country pharmaceutical situations Level I Core structure & process indicators Level II Core outcome/impact indicators <ul><li>Level III </li></ul><ul><li> Indicator tools for specific components </li></ul><ul><li>of the pharmaceutical sector </li></ul><ul><ul><ul><li>Household survey for access </li></ul></ul></ul><ul><ul><ul><li>Pricing ● Traditional medicine </li></ul></ul></ul><ul><ul><ul><li>Assessing regulatory capacity </li></ul></ul></ul><ul><ul><ul><li>Procurement and supply management </li></ul></ul></ul><ul><ul><ul><li>Medicines for children </li></ul></ul></ul>Systematic surveys Questionnaire (Health Officials ) <ul><li>Objectives for seeking evidence </li></ul><ul><li>To prioritize pharmaceutical policy objectives </li></ul><ul><li>To establish evidence for advocacy (managers, policy makers, donors) </li></ul><ul><li>Measure trends over time </li></ul><ul><li>To determine the impact of pharmaceutical policy implementation over time </li></ul>
    5. 5. Status of Community Data Collection WHO health facility survey WHO-HAI pricing survey Price components Household survey Ghana WHO-MeTA May 2008 WHO/HAI A October 2004 WHO/HAI A in process WHO-MeTA May 2008 Jordan May 2004 World Bank planned Kyrgyzstan WHO pre-2004 February 2005 MeTA in process USAID July 2007 Peru May 2002, Sept 2005 World Bank planned Philippines pre-2004, WHO-MeTA May 2008 June 2002, February 2005 WHO-MeTA May 2008 Uganda WHO-MeTA May 2008 WHO/HAI A April 2004 WHO/HAI A August 2007 WHO-MeTA May 2008 Zambia WHO/HAI A October 2006 WHO/HAI A June 2008 WHO/HAI A June 2008 World Bank (TBD)
    6. 6. Sources de Financement Structure d'appro- visionnement 1er point de stockage 2ème point de stockage Structure dispensatrice E T A T B M FONDS MONDIAL C A M E B U D F I D UE U S A I D F N U A P IPPF M S F OM S G F A C E P B U G V C U N I C E F C L I N T O N G T Z G D F C T B C A M E B U I P A A C F C O N C E R N CAMEBU PNLO MSF PNLT CICR CEPBU IMC BPS GVC ACF CORDAID Site de prise en charge CDS SNT/CNT CDT/CT COCOLS BPS CPLS CDV Détaillants CDS Site de prise en charge PNSR CPLS Grossiste Privé CNTS CDV PNSR ACF CORDAID IMC GVC CONCERN PEV PSI P DM C I C R SEP/ CNLS P N L T P S I U N I C E F O M S F N U A P MS F A C F PDM C I C R C E P B U C O R D A I D G V C GTZ CL I NTON UN I TA I D GDF C T B C O N C E R N G A V I K F W I PPF P S I MEDICAMENTS ESSENTIELS ARVs PALUDISME TB IO ARVs Ped REACTIFS sécurité du sang (+ test HIV) VACCINS Préservatifs Contraceptifs Dispositifs Médicaux C O R D A I D SEP/ CNLS ABUBEF PRISON HÔPITAUX Etat Bailleurs multilatéraux Bailleurs bilatéraux ONG/Privé PATIENT
    7. 7. HQ Regional Offices Country Offices Ministries of Health Partners in Country Support WHO operational partners UN agencies e.g. UNDP, UNFPA, UNICEF; NGOs, CSOs WHO scientific partners WHO Collaborating Centres in pharmaceuticals, universities, research centres, international health professional associations WHO strategic partners World Bank and development banks, Donor Agencies e.g. EU, DFID, pharmaceutical industry, WTO, WIPO, TGF, UNITAID Links with partners at global, regional & country level WHO Countries
    8. 8. WHO - HAI Africa Regional Collaboration for Action on Essential Medicines in Africa <ul><li>Goal: Improved equitable and sustainable access to essential medicines </li></ul><ul><li>Purpose: </li></ul><ul><li>Improved policies and practices </li></ul><ul><li>Collaboration among Ministries of Health (MOH), WHO and HAI Africa's network of Civil Society Organisations (CSO's) to increase availability and affordability of medicines in countries & sub-regions </li></ul><ul><li>Outputs: </li></ul><ul><li>Increased capacity of MOH's and CSO's </li></ul><ul><li>Increased participation of CSO's in development of medicines policy and advocacy work </li></ul><ul><li>Access to quality information and increase of collaborative activities related to affordability and availability of medicines in selected countries </li></ul><ul><li>Collaboration mechanisms established at global level and in selected countries </li></ul>